

STANDARD SCIGENICS PRIVATE LIMITED CIN: U26513TS2025PTC204086 Balance sheet as at March 31, 2026 <i>(All amounts are in Rs. Lakhs except share data or unless otherwise stated)</i>			
S.No.	Particulars	Note No	As at March 31, 2026
	ASSETS		
1	Non-current assets		
	(a) Property, Plant and Equipment	3A	50.31
	(b) Capital work-in-progress	3B	-
	(c) Right-of-use assets	4A	-
	(d) Goodwill	4B	833.87
	(e) Other Intangible assets	3C	-
	(f) Financial Assets		
	(i) Other financial assets	5	24.09
	(g) Other non-current assets	10	-
	(h) Deferred tax assets (Net)	6	0.03
	(i) Non Current Tax Assets (Net)	19B	-
	Total Non-current assets		908.30
2	Current assets		
	(a) Inventories	7	454.38
	(b) Financial Assets		
	(i) Trade receivables	8	1,015.59
	(ii) Cash and cash equivalents	9	0.54
	(iii) Bank Balances other than Cash and Cash equivalents	9A	-
	(iii) Loans		-
	(iv) Other financial assets	5	-
	(c) Other current assets	10	47.08
	Total Current assets		1,517.59
	Total Assets		2,425.89
	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	11	1.00
	(b) Other Equity	12	882.38
	Total Equity		883.38
2	LIABILITIES		
	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	13	640.92
	(ii) Lease liabilities	14	-
	(b) Provisions	15	1.13
	Total Non-current liabilities		642.05
	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	13	71.27
	(ii) Lease liabilities	14	-
	(iii) Trade payables		
	(a) Total outstanding dues of micro and small enterprises	16	-
	(b) Total outstanding dues of creditors other than micro and small enterprises	16	496.22
	(iv) Other financial liabilities	17	6.20
	(b) Other current liabilities	18	242.90
	(c) Provisions	15	0.67
	(d) Current Tax Liabilities (Net)	19A	83.20
	Total Current liabilities		900.46
	Total Equity and Liabilities		2,425.89
Summary of material accounting policies		1-2	
As per our report of even date For Sagar & Associates Chartered Accountants Firm Registration Number: 0035105		For and on behalf of the Board of Directors of STANDARD SCIGENICS PRIVATE LIMITED CIN: U29304TG2021PTC155070	
B.Srinivasa Rao Partner Membership Number: 202352		Shanmugasundaram Muthuswamy Managing Director DIN: 01712543	Kandula Krishna Veni Director DIN: 02260233
Place: Hyderabad Date: May 13, 2026			

STANDARD SCIGENICS PRIVATE LIMITED CIN: U26513TS2025PTC204086 Statement of Profits and Loss for the Period ended March 31, 2026 <i>(All amounts are in Rs. Lakhs except share data or unless otherwise stated)</i>			
S.No.	Particulars	Note No	For the Period ended March 31, 2026
I	Revenue from Operations	20	1,850.33
II	Other Income	21	-
III	Total Income (I+II)		1,850.33
IV	Expenses		
	Cost of raw materials consumed	22	1,670.25
	Changes in inventories of finished goods and work-in-progress	23	(438.97)
	Labour charges		46.67
	Employee benefits expenses	24	166.68
	Finance costs	25	28.29
	Depreciation and amortisation expenses	26	2.29
	Other expenses	27	93.73
	Total expenses (IV)		1,568.94
V	Profit before tax (III-IV)		281.39
VI	Tax expense:		
	(1) Current tax	31	80.60
	Income tax relating to earlier years	31	-
	(2) Deferred tax charge/ (benefit)	31	(0.03)
VII	Profit for the year (V-VI)		200.82
VIII	Other Comprehensive Income		
	(i) Items that will not be reclassified to profit or loss		
	Re-measurement gains/ (losses) on defined benefit plans	33	-
	Income tax effect relating to above item		-
	Other comprehensive income for the year, net of tax		-
IX	Total Comprehensive Income for the Year (VII+VIII)		200.82
X	Earnings per equity share		
	(1) Basic Earnings per equity share	30	200.82
	(2) Diluted Earnings per equity share	30	200.82
Summary of material accounting policies		1-2	
As per our report of even date For Sagar & Associates Chartered Accountants Firm Registration Number: 0035105		For and on behalf of the Board of Directors of STANDARD SCIGENICS PRIVATE LIMITED CIN: U29304TG2021PTC155070	
B.Srinivasa Rao Partner Membership Number: 202352		Shanmugasundaram Muthuswamy Managing Director DIN: 01712543	Kandula Krishna Veni Director DIN: 02260233
Place: Hyderabad Date: May 13,2026			

STANDARD SCIGENICS PRIVATE LIMITED CIN: U26513TS2025PTC204086 Statement of Cash Flows for the Period ended March 31, 2026 (All amounts are in Rs. Lakhs except share data or unless otherwise stated)		
Particulars	For the Period ended March 31, 2026	
A. Cash flow from operating activities		
Net Profit Before Tax as per Statement of Profit and Loss	281.39	
Adjustments for :		
Finance costs	28.29	
Interest income	-	
Gain on termination of leases	-	
Depreciation and Amortisation expense	2.29	
Allowance for Expected Credit Loss	-	
Bad debts written off	-	
Provision for advances to vendors	-	
Advances written off	-	
Dividend paid	-	
Operating profit before working capital changes	311.97	
Adjustments for working capital changes in:		
Decrease/ (Increase) Inventories	559.16	
Decrease/ (Increase) Trade receivables	(1,015.59)	
Decrease/ (Increase) Other financial assets	(24.09)	
Decrease/ (Increase) Other assets	(47.08)	
Increase/ (Decrease) Trade payables	496.21	
Increase/ (Decrease) Other liabilities	42.90	
Increase/ (Decrease) Provisions	1.80	
Cash generated from operations	325.28	
Income tax paid (net off refund)	2.60	
Net cash flows generated from operating activities (A)	327.88	
B. Cash flow from investing activities		
Purchase property, plant and equipment (include Capital work in progress)	(0.00)	
Proceeds from sale of property, plant and equipment	-	
Purchase of Intangible Assets	(0.00)	
Interest received	-	
Investments in margin money deposits	-	
On account of business combination	(900.00)	
Net cash flows used in investing activities (B)	(900.01)	
C. Cash flow from financing activities		
Proceeds from issue of equity shares	1.00	
Proceeds from Non-Current borrowings	1,320.36	
Repayment of Non-Current borrowings	-	
Proceeds from / (Repayment of) Current borrowings	(728.73)	
Dividend paid	-	
Interest paid	(19.97)	
Interest on lease liabilities	-	
Principal Portion of Lease liabilities	-	
Net cash flows from financing activities (C)	572.66	
Net Increase/(Decrease) in cash and cash equivalents (A)+(B)+(C)	0.54	
Cash and cash equivalents at the beginning of the year	-	
Cash and cash equivalents at the end of the year	0.54	
Cash and Cash equivalents includes:		
Particulars	For the Period ended March 31, 2026	
Cash on hand	-	
Cash Equivalents - Current accounts	0.54	
Total	0.54	
Summary of material accounting policies 1-2		
As per our report of even date For Sagar & Associates Chartered Accountants Firm Registration Number: 003510S		
For and on behalf of the Board of Directors of STANDARD SCIGENICS PRIVATE LIMITED CIN: U29304TG2021PTC155070		
B.Srinivasa Rao Partner Membership Number: 202352		
Shanmugasundaram Muthuswamy Managing Director DIN: 01712543		
Kandula Krishna Veni Director DIN: 02260233		
Place: Hyderabad Date: May 13,2026		

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

1.1 General Information

Standard Scigenics Private Limited ("the Company") was incorporated on September 16, 2025 and is a subsidiary of Standard Engineering Technology Limited, which is listed on two recognized stock exchanges of India, the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange of India Limited (BSE) on January 13, 2025. . The Company is engaged in the business of manufacturing and selling of stainless steel and nickel/alloy steel reactors, filters, dryers, vessels, and storage tanks for the pharmaceutical industry sector.

The registered office of the Company is located at Door No. 12, Phase-1, IDA, Jeedimetla, IDA Jeedimetla, Tirumalagiri, Hyderabad- 500055,

1.2 Statement of Compliance

These financial statements of the Company have been prepared and presented in accordance with and in compliance in all material aspects, with the Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 ("the Act") read along with the Companies (Indian Accounting Standards) Rules 2015, and presentation requirements of Division II of Schedule III to the Act, and as amended from time to time.

These financial statements have been prepared for the Company as a going concern on the basis of relevant Ind AS that are effective at the reporting date March 31, 2026. These financial statements for the year ended March 31, 2026 were approved by the Company's Board of Directors May 13, 2026.

1.3 Basis of Measurement

These financial statements have been prepared on the historical cost convention and on an accrual basis, except for the following material items in the balance sheet:

- a. Derivative financial instruments are measured at fair value.
- b. Certain financial assets are measured either at fair value or at amortised cost depending on the classification;
- c. Employee defined benefit assets/(liability) are recognised as the net total of the fair value of plan assets, plus actuarial losses, less actuarial gains and the present value of the defined benefit obligation,
- d. Long-term borrowings are measured at amortised cost using the effective interest rate method.; and
- e. right-of-use the assets are recognised at the present value of lease payments that are not paid at that date. This amount is adjusted for any lease payments made at or before the commencement date, lease incentives received and initial direct costs, incurred, if any.

2. Summary of Material accounting policies

2.1 Current and noncurrent classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

All the assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Act and Ind AS 1, Presentation of financial statements.

An asset is classified as current when it satisfies any of the following criteria:

- a. It is expected to be realised in, or is intended for sale or consumption in, the Company's normal operating cycle;
- b. It is held primarily for the purpose of being traded;
- c. It is expected to be realised within twelve months after the reporting date; or
- d. It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

All other assets are classified as non-current.

A liability is classified as current when it satisfies any of the following criteria:

- a. It is expected to be settled in the Company's normal operating cycle;
- b. It is held primarily for the purpose of being traded;
- c. It is due to be settled within twelve months after the reporting date; or
- d. The Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms

of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

The Company classifies all other liabilities as non-current.

Current assets/ liabilities include the current portion of non-current assets/ liabilities respectively. Deferred tax assets and liabilities are always disclosed as non- current.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

2.2 Functional and presentation currency

These financial statements are presented in Indian Rupees (rounded off to nearest lakhs), which is also the functional currency of the Company.

2.3 Fair value measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- in the principal market for the asset or liability, or

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

- in the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the Ind AS financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the Ind AS financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Company's management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for sale in discontinued operations. External valuers are involved, wherever considered necessary. For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above. This note summarises accounting policy for fair value. Other fair value related disclosures are given in the relevant notes.

2.4 Foreign Currency transactions

Transactions in foreign currencies are initially recorded by the Company at their respective functional currency spot rates at the date, the transaction first qualifies for recognition. However, for practical reasons, the Company uses an average rate, if the average approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date. Exchange differences arising on settlement or translation of monetary items are recognised in the Statement of Profit and Loss.

Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the initial transaction.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured.

The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in other comprehensive income ("OCI") or Statement of Profit and Loss are also recognised in OCI or Statement of Profit and Loss, respectively).

2.5 Property Plant & Equipment

Property, Plant and Equipment are stated at cost of acquisition or construction less accumulated depreciation and impairment loss, if any.

Cost includes expenditures that are directly attributable to the acquisition of the asset i.e., freight, duties and taxes applicable and other expenses related to acquisition and installation. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use. Borrowing costs that are directly attributable to the construction or production of a qualifying asset are capitalised as part of the cost of that asset.

The cost of replacing part of an item of property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part will be derecognised. The costs of repairs and maintenance are recognised in the Statement of Profit and Loss as incurred.

Items of stores and spares that meet the definition of Property, Plant and Equipment are capitalised at cost, otherwise, such items are classified as inventories.

When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives.

Items of Property, Plant and Equipment acquired through exchange of non-monetary assets are measured at fair value, unless the exchange transaction lacks commercial substance or the fair value of either the asset received or asset given up is not reliably measurable, in which case the asset exchanged is recorded at the carrying amount of the asset given up.

Depreciation is recognised in the Statement of Profit and Loss on a straight line basis based on the Act ("Schedule II"). For assets acquired or disposed of during the year, depreciation is provided on pro rata basis. Land is not depreciated.

The estimated useful lives are as follows:

STANDARD SCIGENICS PRIVATE LIMITED**Notes forming part of the Financial Statements for the period ended March 31, 2026**

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Type of Asset	Estimated useful life in years
Plant and machinery	15

Insurance/capital/critical stores and spares are depreciated over the remaining useful life of related plant and equipment or useful life of insurance/capital/critical spares, whichever is lower.

An item of Property, Plant and Equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Statement of Profit and Loss when the asset is derecognised.

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted prospectively, if appropriate.

Advances paid towards the acquisition of Property, Plant and Equipment outstanding at each reporting date is disclosed as capital advances under other assets. The cost of Property, Plant and Equipment not ready to use before such date are disclosed under Capital work-in-progress.

Assets not ready for use are not depreciated.

2.6 Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in the Statement of Profit and Loss in the period in which the expenditure is incurred.

Intangible assets are amortised over the useful economic life and assessed for impairment, whenever there is an indication that the Intangible asset may be impaired. The amortisation period and the amortisation method for an Intangible asset are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on Intangible assets is recognised in the Statement of Profit and Loss, unless such expenditure forms part of carrying value of another asset.

Gains or losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

Following initial recognition, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete and the asset is available for use.

Computer Software

The computer software is amortised on a straight-line basis over the useful economic life of 10 years, as estimated by the management.

2.7 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

a. Financial assets**Initial recognition and measurement**

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL);
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

Debt instruments at amortised cost

A 'debt instrument' is measured at amortised cost, if both the following conditions are met: (i) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and (ii) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of Profit and Loss. This category generally applies to trade and other receivables.

Debt instrument at FVTOCI

A 'debt instrument' is classified as FVTOCI, if both the following criteria are met: (i) The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets; and (ii) The asset's contractual cash flows represent SPPI.

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognised in OCI. However, the Company recognises interest income, impairment losses and foreign exchange gain or loss in the Statement of Profit and Loss. On de-recognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to statement of Profit and Loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, that does not meet the criteria for categorisation as at amortised cost or as FVTOCI, is classified as FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

Equity Instruments

All equity investments in the scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as FVTPL. If the Company decides to classify an equity instrument as FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to Statement of Profit and Loss, even on sale of investment. Equity instruments included within the FVTPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e., removed from the Company's balance sheet) when:

- a. The rights to receive cash flows from the asset have expired, or
- b. The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Impairment of Financial Assets

The Company assesses at each balance sheet date whether a financial asset or a group of financial assets is impaired.

In accordance with Ind AS 109, the Company uses "Expected Credit Loss" (ECL) model, for evaluating impairment of Financial Assets other than those measured at Fair Value Through Profit and Loss (FVTPL).

Expected credit losses are measured through a loss allowance at an amount equal to:

- The 12 months expected credit losses (expected credit losses that result from those default events on the financial instrument that are possible within 12 months after the reporting date);
- Full lifetime expected credit losses (expected credit losses that result from all possible default events over the life of the financial instrument)

The Company follows simplified approach for recognition of impairment loss allowance on trade receivables and under the simplified approach, the Company does not track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECL at each reporting date right from its initial recognition. The Company uses a provision matrix to determine impairment loss allowance on trade receivables. The provision matrix is based on its historically observed default rates over the expected life of trade receivable and is adjusted for forward looking estimates. At every reporting date, the historical observed default rates are updated.

For other assets, the Company uses 12-month ECL to provide for impairment loss where there is no significant increase in credit risk. If there is significant increase in credit risk full lifetime ECL is used.

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value i.e., loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts.

Subsequent measurement

The measurement of financial liabilities depends on their classification.

Financial liabilities at fair value through Profit or Loss:

Financial liabilities at fair value through Profit or Loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as fair value through Profit or Loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading, unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognised in the Statement of Profit and Loss.

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/losses attributable to changes in own credit risk are recognised in OCI. These gains/ loss are not subsequently transferred to the Statement of Profit and Loss.

However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the Statement of Profit and Loss.

Loans and borrowings:

Borrowings is the category most relevant to the Company. After initial recognition, interest-bearing borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in the Statement of Profit and Loss when the liabilities are derecognised as well as through the EIR amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the Statement of Profit and Loss.

De-recognition:

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

Reclassification of financial assets and liabilities

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no re-classification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a re-classification is made only if there is a change in the business model for managing those assets. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the re-classification prospectively from the re-classification date, which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet, if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

2.8 Cash & Cash Equivalents

Cash and bank balances comprise of cash balance in hand, in current accounts with banks, and other short-term deposits. For this purpose, "short-term" means investments having maturity of three months or less from the date of investment, and which are subject to an insignificant risk of change in value. Bank overdrafts that are repayable on demand and form an integral part of our cash management are included as a component of cash and cash equivalents for the purpose of the Statement of cash flows.

2.9 Inventories

Inventories are valued at the lower of cost and net realisable value.

Inventories consisting of raw materials, stores and spares, packing materials, work-in-progress and finished goods.

Finished goods and Work-in-Progress are valued at lower of cost and net realisable value.

Raw Materials and Packing Materials are valued at cost on weighted average basis.

Stores & Spares are valued at weighted average cost.

Goods-in-Transit are valued at cost.

Materials and other items held for use in the production of inventories are not written down below cost if the finished goods in which they will be incorporated are expected to be sold at or above cost.

Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition.

In the case of finished goods and work-in-progress, cost includes an appropriate share of overheads based on normal operating capacity. Stores and spares, that do not qualify to be recognised as Property, Plant and Equipment, consists of packing materials, engineering spares (such as machinery spare parts) and consumables which are used in operating machines or consumed as indirect materials in the manufacturing process.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products.

2.10 Impairment of non-financial assets

The carrying amounts of the Company's non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. For

goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year at March 31.

The recoverable amount of an asset or cash-generating unit ("CGU") (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflow of other assets or groups of assets (the "CGU").

STANDARD SCIGENICS PRIVATE LIMITED**Notes forming part of the Financial Statements for the period ended March 31, 2026**

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

The Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to project future cash flows after the fifth year. To estimate cash flow projections beyond periods covered by the most recent budgets/forecasts, the Company extrapolates cash flow projections in the budget using a steady or declining growth rate for subsequent years, unless an increasing rate can be justified. In any case, this growth rate does not exceed the long-term average growth rate for the products, industries, or country in which the entity operates, or for the market in which the asset is used.

An impairment loss is recognised in the Statement of Profit and Loss if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognised in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.

Reversal of Impairment of Assets

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognised in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

2.11 Employee Benefits**Short term employee benefits**

Short-term employee benefits are expensed as the related service is provided. A liability is recognised for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

The Company's contributions to defined contribution plans are charged to the Statement of Profit and Loss as and when the services are received from the employees.

Defined benefit plans

The liability in respect of defined benefit plans and other post-employment benefits is calculated using the projected unit credit method consistent with the report of qualified independent actuaries. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related defined benefit obligation. In countries where there is no deep market in such bonds, the market interest rates on government bonds are used. The current service cost of the defined benefit plan, recognised in the Statement of Profit and Loss in employee benefit expense, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past service costs are recognised immediately in the Statement of Profit and Loss.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of profit and loss. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions for defined benefit obligation and plan assets are recognised in OCI in the period in which they arise. When the benefits under a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognised immediately in the statement of Profit and Loss. The Company recognises gains or losses on the settlement of a defined benefit plan obligation when the settlement occurs.

Termination benefits

Termination benefits are recognised as an expense in the Statement of Profit and Loss when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognised as an expense in the Statement of Profit and Loss if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.

Other long-term employee benefits

The Company's net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognised in the Statement of Profit and Loss in the period in which they arise.

Compensated absences

The Company's current policies permit certain categories of its employees to accumulate and carry forward a portion of their unutilised compensated absences and utilise them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified independent actuary.

The Company treats accumulated leave expected to be carried forward beyond 12 months, as long-term employee benefit for measurement purposes. The Company presents the compensated absences as a current liability in the balance sheet as it does not have an unconditional right to defer its utilisation for 12 months after the reporting date.

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

2.12 Provisions, contingent liabilities and contingent assets

Provisions

A provision is recognised in the Statement of Profit and Loss if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liabilities and contingent assets

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets are not recognised in the financial statements. However, contingent assets are assessed continually and if it is reasonably certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

Onerous contracts

A provision for onerous contracts is recognised in the Statement of Profit and Loss when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognises any impairment loss on the assets associated with that contract.

Reimbursement rights

Expected reimbursements for expenditures required to settle a provision are recognised in the Statement of Profit and Loss only when receipt of such reimbursements is virtually certain. Such reimbursements are recognised as a separate asset in the balance sheet, with a corresponding credit to the specific expense for which the provision has been made.

2.13 Revenue from contracts with customers

Revenue from contracts with customers is recognised when control of the goods is transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods.

Revenue is recognised to the extent that it is probable that economic benefits will flow to the Company and the revenue can be reliably measured regardless of when the payment is being made.

Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of goods sold and services rendered is net of variable consideration on account of rebates and discounts.

Goods and Service Tax (GST) is not received by the Company on its own account and is tax collected on behalf of the government. Accordingly, it is excluded from revenue.

Sale of products

Revenue from sale of product is recognised at the point in time when control of the asset is transferred to the customer, generally on delivery of the product (unless the terms of the contract are otherwise).

Generally, control is transferred upon shipment of goods to the customer or when the goods are made available to the customer, provided transfer of title to the customer occurs and the Company has not retained any significant risks of ownership or future obligations with respect to the goods shipped.

Revenue is measured based on transaction price, which is the fair value of the consideration received or receivable, stated net of discounts, returns and value added tax. Transaction price is recognised based on the price specified in the contract, net of the estimated sales incentives / discounts. In determining the transaction price for the sale of goods, the Company considers the effects of variable consideration, the existence of significant financing components, and consideration payable to the customer (if any).

Sale of services

Service income is recognised, on an accrual basis, at agreed rate in accordance with the terms of the agreement.

Contract balances

Contract assets

A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognised for the earned consideration that is conditional.

Trade receivables

A trade receivable represents the Company's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due).

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Company has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the Company transfers goods or services to the customer, a contract liability is recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Company performs under the contract.

2.14 Interest Income

Interest Income mainly comprises of interest on Margin money deposit with banks relating to bank guarantee and deposits. Interest income should be recorded using the effective interest rate (EIR). However, the amount of margin money deposits relating to bank guarantee are purely current in nature, hence effective interest rate has not been applied. Interest is recognised using the time-proportion method, based on rates implicit in the transactions.

2.15 Borrowing Costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

2.16 Tax Expenses

Tax expense consists of current and deferred tax.

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognised outside the Statement of Profit and Loss is recognised outside the statement of profit and loss (either in OCI or in equity in correlation to the underlying transaction). Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions, where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities and assets are recognised for all taxable temporary differences and deductible temporary differences.

Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside the Statement of Profit and Loss is recognised outside the Statement of Profit and Loss (either in OCI or in equity in correlation to the underlying transaction).

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Goods and Service Tax (GST) paid on acquisition of assets or on incurring expenses

When the tax incurred on purchase of assets or services is not recoverable from the taxation authority, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable. Otherwise, expenses and assets are recognised net of the amount of taxes paid. The net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet.

2.17 Leases

The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company as a lessee

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Right-of-use assets

The Company recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-

use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities.

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received.

Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets. If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

The right-of-use assets are also subject to impairment. Refer to the accounting policies in section of Impairment of non-financial assets.

Lease liabilities

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. The Company's lease liabilities are disclosed separately.

Short-term leases and leases of low-value assets

The Company applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases that are considered to be of low value. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

2.18 Earnings Per Share

Basic earnings per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the year.

The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

2.19 Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognised as income in equal amounts over the expected useful life of the related asset.

2.20 Segment reporting

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the Company), whose operating results are regularly reviewed by the Company's chief operating decision maker (CODM) to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available. Operating segments of the Company are reported in a manner consistent with the internal reporting provided to the CODM.

2.21 Significant accounting judgements, estimates, and assumption

The preparation of the financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. These estimates and associated assumptions are based on historical experiences and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. In particular, the areas involving critical estimates or Judgment are:

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Determining the lease term of contracts with renewal and termination options

The Company determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Company has several lease contracts that include extension and termination options. The Company applies judgement in evaluating whether it is reasonably certain to exercise the option to renew or terminate the lease. That is, it considers all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate. Furthermore, the periods covered by termination options are included as part of the lease term only when they are reasonably certain not to be exercised.

Property, Plant and Equipment

The depreciation of property, plant and equipment is derived on determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. The useful lives and residual values of Company's assets are determined by management at the time of acquisition of asset and is reviewed periodically, including at each financial year end. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life.

Impairment of financial and non-financial assets

Significant management judgement is required to determine the amounts of impairment loss on the financial and non-financial assets. The calculations of impairment loss are sensitive to underlying assumptions.

Tax provisions and contingencies

Significant management judgement is required to determine the amounts of tax provisions and contingencies. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Defined benefit plans

The cost of the defined benefit plan and the present value of the obligation are determined using actuarial valuation. An actuarial valuation involves various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds where remaining maturity of such bond correspond to expected term of defined benefit obligation.

The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates.

Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using internal valuation techniques. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments.

2.22 New Accounting pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2026, MCA has not notified any new standards or amendments to the existing standards applicable to the Company.

STANDARD SCIGENICS PRIVATE LIMITED					
CIN: U26513TS2025PTC204086					
Notes forming part of the Financial Statements for the period ended March 31, 2026					
(All amounts are in Rs. Lakhs except share data or unless otherwise stated)					
STATEMENT OF CHANGES IN EQUITY					
A. Equity Share Capital					
				For the Period ended March 31, 2026	
				No. of shares	Amount
Equity shares of INR 10 each issued, subscribed and fully paid				-	-
Balance as at April 01, 2025				10,000	1.00
Changes in equity share capital during the current year (Note 11)				10,000	1.00
Balance as at March 31, 2026					
				For the Year ended March 31, 2025	
				No. of shares	Amount
Equity shares of INR 10 each issued, subscribed and fully paid				-	-
Balance as at April 01, 2024				-	-
Changes in equity share capital during the current year (Note 11)				-	-
Balance as at March 31, 2025				-	-
B. Other Equity					
Particulars	Equity component of Preference shares/Optionally Convertible Debentures	Reserves and Surplus		Items of Other Comprehensive Income	Total Other Equity
		Capital reserve	Retained Earnings	Re-measurement gains/ (losses) on defined benefit plans	
Balance as at April 01, 2025					
Profit for the year	-	-	200.82	-	200.82
Other comprehensive income for the year(net of taxes)	-	-	-	-	-
On Account Of Ind AS Adjustment	681.56	-	-	-	681.56
Balance as at March 31, 2026	681.56	-	200.82	-	882.38
Nature and purpose of reserves					
Retained earnings					
The balance in the Retained Earnings primarily represents the surplus after payment of dividend and transfer to reserves.					
Re-measurement gains/ (losses) on defined benefit plans					
Remeasurements of the net defined benefits plan reserve comprise the cumulative net gains/ losses on actuarial valuation of post-employment obligations.					
Summary of material accounting policies		1-2			
As per our report of even date		For and on behalf of the Board of Directors of			
For Sagar & Associates		STANDARD SCIGENICS PRIVATE LIMITED			
Chartered Accountants		CIN: U29304TG2021PTC155070			
Firm Registration Number: 003510S					
B.Srinivasa Rao		Shanmugasundaram Muthuswamy		Kandula Krishna Veni	
Partner		Managing Director		Director	
Membership Number: 202352		DIN: 01712543		DIN: 02260233	
Place: Hyderabad					
Date: May 13,2026					

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Note :3A

Property, plant and equipment

Gross carrying amount

Particulars	Plant & Machinery	Furniture & Fixtures	Motor Vehicles	Office Equipment	Computers	Electrical Equipment	Lease hold improvements	Land*	Total
Balance as at March 31, 2024	-	-	-	-	-	-	-	-	-
Additions for the year	-	-	-	-	-	-	-	-	-
Disposals for the year	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2025	-	-	-	-	-	-	-	-	-
Additions for the year	52.60	-	-	-	-	-	-	-	52.60
Disposals for the year	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2026	52.60	-	-	-	-	-	-	-	52.60

Accumulated Depreciation

Particulars	Plant & Machinery	Furniture & Fixtures	Motor Vehicles	Office Equipment	Computers	Electrical Equipment	Lease hold improvements	Land*	Total
Balance as at March 31, 2024	-	-	-	-	-	-	-	-	-
Depreciation charge for the year	-	-	-	-	-	-	-	-	-
On Disposals	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2025	-	-	-	-	-	-	-	-	-
Depreciation charge for the year	2.29	-	-	-	-	-	-	-	2.29
On Disposals	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2026	2.29	-	-	-	-	-	-	-	2.29

Net carrying amount

Particulars	Plant & Machinery	Furniture & Fixtures	Motor Vehicles	Office Equipment	Computers	Electrical Equipment	Lease hold improvements	Land*	Total
As at March 31, 2025	-	-	-	-	-	-	-	-	-
As at March 31, 2026	50.31	-	-	-	-	-	-	-	50.31

Note 4b: Goodwill

Particulars	Goodwill	Total
Gross carrying amount		
Balance as at April 01, 2024	-	-
Additions for the year	833.87	833.87
Disposals for the year	-	-
Balance as at March 31, 2025	833.87	833.87
Additions for the year	-	-
Disposals for the year	-	-
Balance as at March 31, 2026	833.87	833.87

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Note: 5**Other financial assets**

Particulars	As at March 31, 2026		As at March 31, 2025	
	Non-current	Current	Non-current	Current
Unsecured, considered good				
Security Deposits	21.50	-	-	-
Bank deposits with more than twelve months maturity*	-	-	-	-
Interest accrued but not due	-	-	-	-
Advances to Employees	2.59	-	-	-
Total	24.09	-	-	-

*Includes Fixed Deposits created for issuance of Bank Guarantees and Letter of Credits on behalf of the entity.

Note: 6**Deferred tax Assets (net)**

Particulars	As at March 31, 2026	As at March 31, 2025
Deferred tax assets (Refer Note 31)	0.45	
Deferred tax Liabilities (Refer Note 31)	(0.42)	
Deferred tax Assets (net)	0.03	-

Note: 7**Inventories**

Particulars	As at March 31, 2026	As at March 31, 2025
Raw materials	15.41	-
Work-in-progress	438.97	-
Consumable stores and spares	-	-
Total	454.38	-

Note: 8**Trade receivables**

Particulars	As at March 31, 2026	As at March 31, 2025
Trade receivables considered good - unsecured	1,015.59	
Less: Allowance against expected credit loss	-	
Total	1,015.59	-

Amount due from related parties out of the trade receivables (Refer Note: 34) 1,015.59

Trade Receivable Aging Schedule as at March 31, 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed trade receivables - considered good	1,015.59	-	-	-	-	1,015.59
(ii) Undisputed trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables - considered good	-	-	-	-	-	-
(iv) Disputed trade receivables - considered doubtful	-	-	-	-	-	-
Less: Allowance against expected credit loss	-	-	-	-	-	-
Total	1,015.59	-	-	-	-	1,015.59

Trade Receivable Aging Schedule as at March 31, 2025

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed trade receivables - considered good						-
(ii) Undisputed trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables - considered good	-	-	-	-	-	-
(iv) Disputed trade receivables - considered doubtful	-	-	-	-	-	-
Less: Allowance against expected credit loss						-
Total	-	-	-	-	-	-

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Note: 9**Cash and cash equivalents**

Particulars	As at March 31, 2026	As at March 31, 2025
Cash on hand	-	
Balances with banks- in current accounts	0.54	
Total	0.54	-

Note: 9A**Bank Balances other than Cash and Cash equivalents**

Particulars	As at March 31, 2026	As at March 31, 2025
Margin Money Deposits with original maturity less than 12 months*	-	
Total	-	-

* Margin Money Deposits represents the Fixed Deposits created for issuance of Bank Guarantees and Letter of Credits on behalf of the entity.

Note: 10**Other assets**

Particulars	As at March 31, 2026		As at March 31, 2025	
	Non-current	Current	Non-current	Current
Unsecured, Considered good				
Capital Advances (Also refer note 42)	-	-		
Security Deposits	-	-		
Advances to vendors	-	45.02		
Prepaid expenses	-	0.21		
Balances with government authorities	-	1.85		
Total	-	47.08	-	-

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Note:11

Share Capital
A. Equity Shares

Particulars	As at March 31, 2026	
	No of Shares	Amount in Rs
Authorised		
Equity shares of Rs 10/- each	10,000	1.00
Issued, subscribed and paid-up capital		
Equity shares of Rs 10/- each fully paid up	10,000	1.00
Total issued, subscribed and fully paid-up Equity shares	10,000	1.00

(a) Reconciliation of the shares outstanding at the beginning and at the end of the reporting period
Equity Shares

Particulars	As at March 31, 2026	
	No of Shares	Amount in Rs
At the beginning of the period	-	-
Issued during the period	10,000.00	1.00
Outstanding at the end of the period	10,000	1.00

(b) Terms / rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10/-. The each share holder is entitled to, one vote per share and the amount of dividend declared if any, by the Board of Directors. In the event of liquidation of Company, the holders of equity shares will be entitled to receive remaining net assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by each shareholder.

(c) Details of shareholders holding more than 5% of the equity shares of the company

Name of the Shareholders	As at March 31, 2026	
	No of Shares	% of share holding
Standard Engineering Technology Limited	5,100	51.00
Mr Shanmugasundaram Muthuswamy	2,450	24.50
Mr Nadhini Ramalingam	2,450	24.50

As per records of the company, including its register of shareholders/ members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

(d) Details of Shares held by holding company

Particulars	As at March 31, 2026	
	No of Shares	% of share holding
Standard Engineering Technology Limited, the Holding Company		
Equity Shares of Rs. 10 each fully paid	5,100	51.00

e) Details of shares held by Promoters of the company at the end of the year

Name of the Shareholders	As at March 31, 2026	
	No of Shares	% of share holding
Equity Shares		
Standard Engineering Technology Limited	5,100	51.00
Mr Shanmugasundaram Muthuswamy	2,450	24.50
Mr Nadhini Ramalingam	2,450	24.50

(f) No class of shares have been issued as bonus shares or for consideration other than cash by the Company during the period of five years immediately preceding the current year end.

(g) No class of shares have been bought back by the Company during the period of five years immediately preceding the current year end.

STANDARD SCIGENICS PRIVATE LIMITED
Notes forming part of the Financial Statements for the period ended March 31, 2026
(All amounts are in Rs. Lakhs except share data or unless otherwise stated)
Note:12
Other Equity

Particulars	Equity component of Preference shares/Optionally Convertible Debentures	Reserves and Surplus		Items of Other Comprehensive Income	Total Other Equity
		Capital reserve	Retained Earnings	Re-measurement gains/ (losses) on defined benefit plans	
Balance as at March 31, 2024	-	-	-	-	-
Profit for the year	-	-	-	-	-
Other comprehensive income for the year (net of taxes)	-	-	-	-	-
On Account Of Ind AS Adjustment	-	-	-	-	-
Balance as at March 31, 2025	-	-	-	-	-
Profit for the year	-	-	200.82	-	200.82
Other comprehensive income for the year (net of taxes)	-	-	-	-	-
On Account Of Ind AS Adjustment	681.56	-	-	-	681.56
Balance as at March 31, 2026	681.56	-	200.82	-	882.38

Note:13
Non-current Borrowings

Particulars	As at March 31, 2026
Term loans (Secured, at amortised cost)	
Term loans from bank (secured)	-
Other loans(Unsecured, at amortised cost)	
Loan from Holding Company*	542.63
Loan from related parties**	98.29
Debenture Application Money*	-
Total	640.92

*During the year ended March 31, 2026, the Company has allotted 0.01% Optionally Convertible Debentures (OCDs) against debenture application money received from its holding company. The OCDs have a face value of Rs. 1,00,000 each aggregating to Rs. 1,108.00 lakhs. As per Ind AS 109, these instruments were fair valued, resulting in a fair valuation adjustment of Rs. 542.60 lakhs (including interest impact), which has been recognised in the financial statements and treated as borrowings.

**During the year ended March 31, 2026, the Company has allotted 0.01% Optionally Convertible Debentures (OCDs) against debenture application money received from its Directors Mr Muthuswami & Nandhini. The OCDs have a face value of Rs. 1,00,000 each aggregating to Rs.114 lakhs and 86.00 lakhs respectively. As per Ind AS 109, these instruments were fair valued, resulting in a fair valuation adjustment of Rs. 56.22 lakhs & 42.06 lakhs respectively (including interest impact) , which has been recognised in the financial statements and treated as borrowings.

Note:13
Current Borrowings

Particulars	As at March 31, 2026
Secured	
Cash credit facility from bank (secured)	71.27
Current maturities of Non-Current borrowings	-
Total	71.27

Note:

- Cash Credit from banks carry an interest ranging from 7.91% per annum.
- Cash credit facilities from banks are secured by hypothecation of the Company's entire current assets, both present and future, along with an exclusive charge on the Company's fixed assets. The facilities are further secured by a corporate guarantee provided by Standard Engineering Technology Limited (Formerly known as Standard Glass Lining Technology Limited) .
- Cash credit loan and term loans have been guaranteed by Standard Engineering Technology Limited (Parent company).
- Cash credit facilities obtained from the bank during the year were used for the general corporate purpose and working capital management.

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Note 14
Lease Liabilities

Particulars	As at March 31, 2026	
	Non current	Current
Lease liability (Refer Note 43)	-	-
Total	-	-

Note:15
Provisions

Particulars	As at March 31, 2026	
	Non-current	Current
Provision for gratuity (funded) (Refer note 33)	-	-
Provision for compensated absences (Refer note 33)	1.13	0.67
Total	1.13	0.67

Note: 16
Trade payables

Particulars	As at March 31, 2026
Total outstanding dues of micro enterprises and small enterprises (MSME)	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	496.22
Total	496.22

Amount due to related parties out of the trade payables (Refer Note: 34)

-

Trade payables ageing schedule as at March 31, 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Billed but not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-	-
(ii) Disputed dues - MSME	496.22	-	-	-	-	-
(iii) Others	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
Total	496.22	-	-	-	-	-

Based on the information available with the Company, there are no outstanding dues and payments made to any supplier of goods and services beyond the specified period under Micro, Small and Medium Enterprises Development Act, 2006 [MSMED Act]. There is no interest payable or paid to any suppliers under the said Act for the year ended March 31, 2026.

Disclosure under the Micro, Small and Medium Enterprises Development Act, 2006

The Company has certain dues to suppliers (trade and capital) registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows:

Particulars	As at March 31, 2026
(a) The principal amount and the interest due thereon remaining unpaid to any supplier registered under the MSMED Act at the end of each accounting year; - Principal amount (including capital creditors) - Interest amount	- - -
(b) The amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;	-
(c) The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;	-
(d) The amount of interest accrued and remaining unpaid at the end of each accounting year	-
(e) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006.	-
Total	-

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Note:17

Other financial liabilities

Particulars	As at March 31, 2026	
	Non-current	Current
Capital creditors	-	-
Interest accrued	-	6.20
Total	-	6.20

Note:18

Other liabilities

Particulars	As at March 31, 2026	
	Non-current	Current
Statutory dues payable	-	105.40
Advance from customers	-	137.50
Total	-	242.90

Note:19A

Current tax liabilities (Net)

Particulars	As at March 31, 2026
Provision for taxes (net of Advance tax and withholding taxes)	-
Total	-

Note:19B

Non Current Tax Assets (Net)

Particulars	As at March 31, 2026
Non Current Tax Assets (Net of Provision for taxes)	83.20
Total	83.20

STANDARD SCIGENICS PRIVATE LIMITED Notes forming part of the Financial Statements for the period ended March 31, 2026 <i>(All amounts are in Rs. Lakhs except share data or unless otherwise stated)</i>	
Note :20 Revenue from Operations	
Particulars	For the Period ended March 31,2026
Revenue from contracts with customers(Refer note 29)	
Sale of products	1,789.73
Sale of services	60.60
Other Operating Revenue	
Scrap Sales	-
Total	1,850.33
Note : 21 Other income	
Particulars	For the Period ended March 31,2026
Income from Chit Fund	-
Interest income	
- Bank Deposits	-
- other Deposits	-
Miscellaneous income	-
Total	-
Note : 22 Cost of raw material consumed	
Particulars	For the Period ended March 31,2026
Inventory at the beginning of the period	-
Add: Purchases	1,685.66
Less: Inventory at the end of the period	15.41
Consumption	1,670.25
Note : 23 Changes in inventories of finished goods	
Particulars	For the Period ended March 31,2026
Inventory at the beginning of the period	
Work in Progress	-
Inventory at the ending of the period	
Work in Progress	438.97
Increase in stock	(438.97)
Note: 24 Employee benefits expense	
Particulars	For the Period ended March 31,2026
Salaries, wages and bonus	159.35
Contribution to provident and other funds (Refer note 33)	5.60
Gratuity expenses (Refer note 33)	-
Staff welfare expenses	1.73
Total	166.68
Note: 25 Finance cost	
Particulars	For the Period ended March 31,2026
Interest expense on borrowing measured at amortised cost	21.90
Other finance costs	6.39
Total	28.29

STANDARD SCIGENICS PRIVATE LIMITED	
Notes forming part of the Financial Statements for the period ended March 31, 2026	
(All amounts are in Rs. Lakhs except share data or unless otherwise stated)	
Note: 26 Depreciation and amortisation expenses	
Particulars	For the Period ended March 31,2026
Depreciation on property, plant and equipment (Refer Note 3A)	2.29
Total	2.29
Note 27 Other expenses	
Particulars	For the Period ended March 31,2026
Power and fuel	2.44
Rent (Refer Note 43)	10.86
Repairs and maintenance	0.31
Security charges	0.81
Water charges	0.20
Rates and taxes	0.03
Legal and professional fees	5.37
Travelling and conveyance	3.48
Payment to auditor*	2.00
Miscellaneous expenses	0.36
Advertising and sales promotion	0.87
Installation & Commissioning Expenses	67.00
Total	93.73
*Note : The following is the break-up of Auditors remuneration (exclusive of goods and service tax)	
Particulars	For the Period ended March 31,2026
Audit fees*	2.00
TOTAL	2.00
*Excluding Out of Pocket Expenses and applicable taxes.	

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

28 Changes in liabilities arising from financing activities

For the Period ended March 31, 2026

Particulars	Current		Non-current	
	Borrowings	Lease liabilities	Borrowings	Lease liabilities
April 01, 2025	-	-	-	-
Cash flows (Net)	71.27	-	640.92	-
Interest accrual and lease payments, net	-	-	-	-
March 31, 2026	71.27	-	640.92	-

29 Revenue from Operations

Disaggregated revenue information

Particulars	For the Period ended March 31, 2026
Revenue from Operations	
Sale of products	1,789.73
Sale of services	60.60
Other operating revenues (scrap sales)	-
Total	1,850.33
(a) Disaggregated revenue information	
India	1,850.33
Outside India	-
	1,850.33
(b) Timing of revenue recognition	
Products transferred for a point in time	1,789.73
Services rendered over a point of time	60.60
	1,850.33
(c) Reconciliation of amount of revenue	
Revenue as per contracted price (including	1,850.33
Adjustments	
Rebates	-
Sales Returns	-
Revenue from Operations	1,850.33

30 Earning per Share

Particulars	For the Period ended March 31, 2026
Earnings	
Profit attributable to equity holders	200.82
Shares	
Number of shares at the beginning of the year	-
Add: Equity shares issued	1
Less: Buy back of equity shares	-
Total number of equity shares outstanding at the end of the year	1
Weighted average number of equity shares	1
Basic earnings per share of par value Rs 10/-	200.82
Diluted earnings per share of par value Rs 10/-	200.82

31 Taxes

Income tax expense:

The major components of income tax expense are:

Statement of Profit and Loss

Particulars	For the Period ended March 31, 2026
Current tax	80.60
Income tax relating to earlier years	-
Deferred tax charge/(benefit)	(0.03)
Total income tax expense recognised in Statement of Profit and Loss	80.57

STANDARD SCIGENICS PRIVATE LIMITED
Notes forming part of the Financial Statements for the period ended March 31, 2026
(All amounts are in Rs. Lakhs except share data or unless otherwise stated)
Other comprehensive income (OCI)

Particulars	For the Period ended March 31,2026
Gains/ (Losses) on Remeasurement of defined benefit plans	-

Reconciliation of effective tax rate:

Particulars	For the Period ended March 31,2026
Profit before tax	281.39
Enacted tax rate in India	25.17%
Expected tax expense	70.82
Permanent Difference	
Expenses disallowed under Income tax Act, 1961	0.65
On account of prior period tax expense	-
On account of IND AS Adjustment impact	3.60
Others	5.53
	9.78
Income tax expense reported in the statement of profit and loss	80.60
	80.60
Effective Income tax rate	28.64%

Deferred tax relates to the following:

	Balance Sheet
	March 31, 2026
Deferred tax liabilities:	0.42
WDV differences of assets as per books and tax	0.42
Loan processing charges	-
Deferred tax assets:	(0.45)
Provision for Gratuity and Compensated absences	(0.45)
Provision for Expected credit loss	-
Provision for Advances	-
Net of right of use of asset and lease liability	-
Net deferred tax (assets)/liabilities	(0.03)
Reflected in the balance sheet as follows:	
Deferred tax assets (continuing operations)	(0.45)
Deferred tax liabilities:	
Continuing operations	0.42
Deferred tax liabilities/(Asset) (Net)	(0.03)

32 Segment information

The Managing Director of the Company has been identified as being the Chief Operating Decision Maker (CODM). In the opinion of the CODM, the Company has only one operating segment i.e., is engaged in manufacturing and selling of heavy engineering Equipments for the pharmaceutical industry sector. Hence, the same becomes the reportable segment for the Company. Accordingly, disclosure of segment information as prescribed in the Indian Accounting Standard 108 "Operating segments" is not applicable.

33 Employee benefits
Defined Contribution Plan:

Contributions were made to provident fund and employee state insurance in India for the employees of the Company as per the regulations. These contributions are made to registered funds administered by the Government of India. The obligation of the Company is limited to the amount contributed and it has no further contractual nor any other constructive obligation.

Particulars	For the Period ended March 31,2026
Employers Contribution to Provident fund	5.51
Employers Contribution to Employee state insurance	0.09
Total	5.60

STANDARD SCIGENICS PRIVATE LIMITED
Notes forming part of the Financial Statements for the period ended March 31, 2026
(All amounts are in Rs. Lakhs except share data or unless otherwise stated)
Compensated absences

The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof as per the Company's policy. The Company records a liability for compensated absences in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this obligation was Rs. 1.80 Lakhs as at March 31, 2026.

34 Related party disclosures
List of related parties and nature of relationship

Related parties where control /Significant influence exists	Nature of Relationship
Standard Engineering Technology Limited formerly known as	Holding company
Standard Flora Private Limited	Fellow Subsidiary
Standard Engineering Solutions Private Limited	Fellow Subsidiary
CPK Engineers and Equipment Private Limited	Fellow Subsidiary
Standard C2C Engineering Private Limited	Fellow Subsidiary
S2 Engineering Industry Private Limited	Fellow Subsidiary
Stanseals Private Limited	Enterprises owned or significantly influenced by KMP or their relatives
S2 Engineering Services	Enterprises owned or significantly influenced by KMP or their relatives
S2 Engineering Equipment	Enterprises owned or significantly influenced by KMP or their relatives
Stanpumps Engineering Industries	Enterprises owned or significantly influenced by KMP or their relatives
Standard Holdings	Enterprises owned or significantly influenced by KMP or their relatives
Sri Krishna Equipments	Enterprises owned or significantly influenced by KMP or their relatives
Standard Equipment Leasing Services	Enterprises owned or significantly influenced by KMP or their relatives
Schematic Engineering Industries	Enterprises owned or significantly influenced by KMP or their relatives
Schematic Engineering Industries Private Limited	Enterprises owned or significantly influenced by KMP or their relatives
Stanvalves & Controls Pvt Limited	Enterprises owned or significantly influenced by KMP or their relatives
Standard Group of Companies Private Limited	Enterprises owned or significantly influenced by KMP or their relatives
Stylosoft LLP	Enterprises owned or significantly influenced by KMP or their relatives
Sri Varun Fabrication	Enterprises owned or significantly influenced by KMP or their relatives
Key Management personnel (KMP)	
Mr Shanmugasundaram Muthuswamy	Managing Director
Mr. Kandula Ramakrishna	Director
Mrs. Kandula Krishna Veni	Director
Mr Nadhini Ramalingam	Director
Mr Talluri Surendra	Director
Mr. Kandula Nageswara Rao	Relative of KMP

Related parties disclosures
Related party transactions during the year

Particulars	For the Period ended March 31, 2026
Remuneration paid to KMPs and their relatives	17.07
Rent Expense	
Scigenics (India) Private Limited	10.00
Sales of goods	
Scigenics (India) Private Limited	1,789.73
Purchase of goods	
S2 Engineering Industry Private Limited	19.39
Scigenics (India) Private Limited	633.71
Receipt of Services	
Scigenics (India) Private Limited	50.87
S2 Engineering Industry Private Limited	3.36
Standard Group of Companies Private Limited	
Rendering of services	
Scigenics (India) Private Limited	61.72
Loans taken from	
Standard Engineering Technology Limited	900.16
Loan Converted to Optionally Convertible Debentures	
Standard Engineering Technology Limited	900.00
Business Acquired on Slumpsale	
Scigenics (India) Private Limited	900.00

STANDARD SCIGENICS PRIVATE LIMITED
Notes forming part of the Financial Statements for the period ended March 31, 2026
(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Rental Deposit Given	
Scigenics (India) Private Limited	12.00
Optionally Convertible Debentures Issued	
Standard Engineering Technology Limited	208.00
Nadhini Ramalingam	86.00
Shanmugasundaram Muthuswamy	114.00
Interest Expenses	
Standard Engineering Technology Limited	6.88
Nadhini Ramalingam	-
Shanmugasundaram Muthuswamy	-
Share capital infusion	
Standard Engineering Technology Limited	0.51
Nadhini Ramalingam	0.21
Shanmugasundaram Muthuswamy	0.28
Corporate guarantee taken from	
Standard Engineering Technology Limited	1,500.00

Outstanding balances as at year end

Particulars	For the Period ended March 31, 2026
Payables	
S2 Engineering Industry private Limited	26.51
Receivables	
Scigenics (India) Private Limited	1,015.59
Rental Deposit Receivable	
Scigenics (India) Private Limited	12.00
Slump Sale Consideration payable	
Scigenics (India) Private Limited	188.60
Loan Repayable	
Standard Engineering Technology Limited	0.16
Interest Payable	
Standard Engineering Technology Limited	6.19
Nadhini Ramalingam	-
Shanmugasundaram Muthuswamy	-
Investment of Standard Glass Lining Technology Limited	1,108.00
Investment of Nadhini Ramalingam	86.00
Investment of Shanmugasundaram Muthuswamy	114.00
Corporate guarantee taken from	
Standard Engineering Technology Limited	293.57

35 Transactions in foreign currency

Particulars	For the Period ended March 31, 2026
CIF value of Imports	
Import of goods	-
Earnings in Foreign currency :	
FOB value of Exports	-
Expenditure in Foreign Currency:	
Subscriptions and renewals	-

"The Company did not have any foreign currency transactions during the year."
36 Financial instruments and fair value

All assets and liabilities for which fair value is measured or disclosed in the Ind AS financial statements are categorised within the fair value hierarchy, as below, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 : Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 : Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 : Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

Financial instruments by category

The carrying value and fair value of financial instruments were as follows:

Particulars	For the Period ended March 31, 2026	
	Total carrying value	Total fair value
Assets:		
Cash and bank balances	0.54	0.54
Trade and other receivables	1,015.59	1,015.59
Other financial assets	24.09	24.09
Total	1,040.22	1,040.22
Liabilities:		
Trade and other payables	496.22	496.22
Borrowings	712.19	712.19
Lease liabilities	-	-
Other financial liabilities	6.20	6.20
Total	1,214.61	1,214.61

There has been no transfers between levels during the year. The fair values of derivatives are based on derived mark-to-market values. The management has assessed that the carrying values of financial assets and financial liabilities for which fair values are disclosed, reasonably approximate their fair values because these instruments have short-term maturities.

Borrowings include Indian currency long-term loans wherein interest rates are linked to benchmark rates (Marginal Cost of Lending Rates/Prime Lending Rates) of respective lenders. These benchmark rates are determined based on cost of funds of the lenders, as well as, market rates. The benchmark rates are periodically revised by the lenders to reflect prevalent market conditions. Accordingly, effective cost of debt for borrowings at any point of time is in line with the prevalent market rates. Due to these reasons, management is of the opinion that they can achieve refinancing, if required, at similar cost of debt, as current effective interest rates. Hence, the discounting rate for calculating the fair value of borrowings has been taken in line with the current cost of debt.

37 Financial risk management objectives and policies

The Company's principal financial liabilities comprise borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include investments, trade and other receivables, cash and cash equivalents, bank balances, security deposits and derivatives that are out of regular business operations.

The Company is exposed to market risk, credit risk and liquidity risk. The Company's senior management oversees the management of these risks. The Company's risk management is carried out by a treasury department under policies approved by the Board of Directors. The Board of Directors provides written principles for overall risk management, as well as policies covering specific areas, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments, and investment of excess liquidity.

(a) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument that will fluctuate because of changes in market prices. Market risk comprises three types of risk i.e. interest rate risk, currency risk and other price risk, such as commodity risk. Financial instruments affected by market risk include borrowings, derivatives financial instruments and trade payables.

i. Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of the Company's financial instruments will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rate relates primarily to the Company's borrowings with floating interest rates. The following table demonstrates the sensitivity to a reasonably possible change in interest rates on borrowings affected. With all other variables held constant, the Company's profit before tax is affected through the impact on floating rate borrowings, without considering impact of derivatives not designated as hedges, as follows:

	Increase/decrease in basis points	Effect on profit before tax
	March 31, 2026	Rs in Lakhs
INR	100.00	(0.08)
INR	(100.00)	0.08

ii. Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's foreign currency borrowings and trade payables. The summary of derivative instruments and unhedged foreign currency exposure is as below:

Derivatives (not designated as hedges) outstanding as at the reporting date

Type	Currency	For the Period ended March 31, 2026	
		Foreign currency in Lakhs	Rs. in Lakhs
Cross currency swaps	EURO	-	-
Interest rate swaps	EURO	-	-
Forward contracts	USD	-	-

"The Company did not have any foreign currency transactions during the year."

STANDARD SCIGENICS PRIVATE LIMITED
Notes forming part of the Financial Statements for the period ended March 31, 2026
(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

Un-hedged foreign currency exposure as at the end of reporting period:

Particulars	Currency	For the Period ended March 31, 2026	
		Foreign currency (in Lakhs)	Rs. in Lakhs
Advances Received	USD	-	-
Trade payables	USD	-	-
Advances given	USD	-	-
Advances given	EURO	-	-

The following tables demonstrate the sensitivity to a reasonably possible change in foreign exchange rates, with all other variables held constant and without considering impact of derivatives not designated as hedges:

Particulars	For the Period ended March 31, 2026	
	5% increase	5% decrease
Impact on profit before tax		
USD	-	-
EURO	-	-

(b) Credit risk

Credit risk is the risk of loss that may arise on outstanding financial instruments if a counterparty default on its obligations. The Company's exposure to credit risk arises majorly from trade and other receivables. Other financial assets like security deposits and bank deposits are mostly with government authorities and scheduled banks and hence, the Company does not expect any credit risk with respect to these financial assets.

Trade and other receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business.

Investments

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counter-parties that have a good credit rating. The Company does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

Details of financial assets - not due, past due and impaired

None of the Company's cash equivalents, including term deposits with banks, were past due or impaired as of March 31, 2025. The Company's credit period for trade and other receivables payable by its customers generally ranges from 30 to 90 days.

The ageing of trade and other receivables is given below:

Reconciliation of impairment of trade receivables and other assets

Particulars	For the Period ended March 31, 2026
Impairment of Trade receivable	
Balance at the beginning of the year	-
Add: Provision made during the year	-
Less: Reversal of earlier years provisions	-
Less: Bad debts written off from earlier years provisions	-
Balance at the end of the year	-

(c) Liquidity risk

The Company's objective is to maintain optimum levels of liquidity to meet its cash and collateral requirements at all times. The Company relies on a mix of borrowings and excess operating cash flows to meet its needs for funds. The current committed lines of credit are sufficient to meet its short to medium/long term expansion needs. The Company monitors rolling forecasts of its liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Company does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities.

The table below summarises the maturity profile of the Company's financial liabilities on undiscounted basis:

Particulars	Up to 1 year	1-3 years	3-5 years	Above 5 years	Total
March 31, 2026					
Non-current borrowings	-	-	-	640.92	640.92
Lease liabilities	-	-	-	-	-
Current borrowings	71.27	-	-	-	71.27
Trade payables	496.22	-	-	-	496.22
Other financial liabilities	6.20	-	-	-	6.20
Total	573.69	-	-	640.92	1,214.61

STANDARD SCIGENICS PRIVATE LIMITED
Notes forming part of the Financial Statements for the period ended March 31, 2026
(All amounts are in Rs. Lakhs except share data or unless otherwise stated)
38 Ratio Analysis:

Ratio	Numerator	Denominator	For the Period ended March 31, 2026	Variance (%)
Current ratio	Current Assets	Current Liabilities	1.69	0.00%
Debt- Equity Ratio	Total Debt	Shareholder's Equity	0.81	0.00%
Debt Service Coverage ratio	Earnings for debt service	Debt service	4.38	0.00%
Return on Equity ratio	Net Profits after taxes	Average Shareholder's Equity	0.45	0.00%
Inventory Turnover ratio	Cost of goods sold	Average Inventory	5.42	0.00%
Trade Receivable Turnover Ratio	Revenue	Average Trade Receivable	3.64	0.00%
Trade Payable Turnover Ratio	Net credit purchases	Average Trade Payables	3.40	0.00%
Net Capital Turnover Ratio	Revenue	Working capital	3.00	0.00%
Net Profit ratio	Net Profit	Revenue	0.11	0.00%
Return on Capital Employed	Earnings before interest and taxes	Capital Employed	0.19	0.00%

Note : All the ratios are calculated in terms of times & The Company has been incorporated during the current financial year. Accordingly, comparative figures for the previous year are not available, and hence variance analysis for ratios is not applicable

39 Other statutory information

(i) The Company has been allotted land by TSIC for setting up manufacturing facility. The agreement is entered into with the authority and possession obtained. Pursuant to the terms and conditions the registration of the land in the name of the Company would be made once the facility commences commercial operations. Also refer foot note 3A.

(ii) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(iii) The Company does not have any transactions with struck off the act.

(iv) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(v) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

(vi) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(vii) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(viii) The Company has not entered in to any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

(ix) The Company has not been declared as wilful defaulter by any bank or financial institution or other lender.

(x) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

(xi) No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Act, during the year.

(xii) Quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts.

(xiii) The Company has not revalued its Property Plant and Equipment and Intangible assets during the year.

(xiv) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India and the Group does not have any CICs, which are part of the Group.

(xv) The Company uses an accounting software, Tally, for maintaining its books of account during the year ended March 31, 2025, which has a feature of recording audit trail (edit log) facility, and the same has been enabled and operated through out the year for all the relevant transactions recorded in the accounting software.

40 Capital Management

For the purpose of the Company's capital management, capital includes issued equity capital, convertible preference shares, securities premium and all other equity reserves attributable to the equity holders of the parent. The primary objective of the Company's capital management is to maximise the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings, less cash and cash equivalents, excluding discontinued operations.

Particulars	For the Period ended March 31, 2026
Borrowings	640.92
Lease liabilities	-
Current borrowing	71.27
Less: cash and cash equivalents	0.54
Net debt	711.65
Equity share capital	1.00
Other equity	882.38
Total capital	883.38
Capital and net debt	1,595.03
Gearing ratio	0.45

STANDARD SCIGENICS PRIVATE LIMITED

Notes forming part of the Financial Statements for the period ended March 31, 2026

(All amounts are in Rs. Lakhs except share data or unless otherwise stated)

41 Commitments and Contingent Liabilities

Particulars	For the Period ended March 31,2026
Capital and other commitments	
(a) Estimated amount of contract remaining to be executed (net of capital advances) on capital account and not provided for	-
Contingent liabilities	
Claims against the company not acknowledge as debts	
a) Bank Guarantee	-
b) Letter of Credits issued but not Accepted	-
c) Towards demand for stamp duty by Collector	-

42 Leases:

The Company has certain leases with lease terms of 12 months or less and leases with low value. The Company applies the 'short-term lease' and 'lease of low-value assets' recognition exemptions for these leases.

Particulars	For the Period ended March 31,2026
At the beginning of the year	-
Additions	-
Lease terminated	-
Accretion of interest	-
Payments	-
At the end of the year	-
Current	-
Non-current	-

The maturity analysis of lease liabilities is disclosed in Note 37. The following are the amounts recognised in the statement of profit or loss:

Depreciation expense of right-of-use assets	-
Interest expense on lease liabilities	-
Expense relating to short-term leases	10.86
Total amount recognised in the P&L account	10.86

The Company had total cash outflows for leases of Rs. 10.86 Lakhs .

Particulars	For the Period ended March 31,2026
Expense relating to leases of low-value assets	-
Expense relating to short-term leases	10.86
Variable lease payments	-
Total Lease Payments not considered as Lease payments under Ind AS 116	10.86

During the Year ended March 31,2026, the Company has acquired the business of Scigenics (India) Private Limited on a slump sale basis vide Business Transfer agreement dated October 31, 2025 for consideration amounting to Rs. 900.00 Lakhs on a going concern basis.

43

Details of Assets and liabilities acquired on a slump sale basis

Particulars	Amount
Assets	
Fixed Assets	52.59
Current assets	1,013.54
Total	1,066.13
Liabilities	
Non Current liabilities	
Current liabilities	1,000.00
Total	1,000.00
Net assets acquired	66.13

44 Previous year figures have been regrouped/re-classified wherever necessary, to conform to current year's classification.

As per our report of even date
For Sagar & Associates
Chartered Accountants
Firm Registration Number: 0035105

For and on behalf of the Board of Directors of
STANDARD SCIGENICS PRIVATE LIMITED
CIN: U29304TG2021PTC155070

B.Srinivasa Rao
Partner
Membership Number: 202352

Shanmugasundaram Muthuswamy
Managing Director
DIN: 01712543

Kandula Krishna Veni
Director
DIN: 02260233

Place: Hyderabad
Date: May 13,2026